



DAFTAR PUSTAKA

- Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F., 2003, Prospective identification of tumorigenic breast cancer cells. dalam *Proceedings of the National Academy of Sciences of the United States of America*, 100(7), 3983–3988. <https://doi.org/10.1073/pnas.0530291100>
- Ami, A. P., 2019, *Manajemen Kanker Payudara Komprehensif*, Airlangga University Press, Surabaya.
- Amin, M.B., dan Edge, S.B., 2017, *AJCC cancer staging manual*, 4–96, Springer International Publishing, Swiss.
- Anwar, A. D., 2013, *BCCOG 2013: Bandung Controversies And Consensus In Obstetrics & Gynecology*, Sagung Seto, Jakarta.
- Bardal, S. K., Waechter, J. E., & Martin, D. S., 2011, *Neoplasia. Applied Pharmacology*, 305–324, W.B. Saunders, Amerika
- Baselga, J., dkk., 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, dalam *The New England journal of medicine*, 366(6), 520–529. <https://doi.org/10.1056/NEJMoa1109653>
- Blakemore, J., dan Naftolin, F., 2016, Aromatase: Contributions to Physiology and Disease in Women and Men, dalam *Physiology*, 31(4), 258–269. <https://doi.org/10.1152/physiol.00054.2015>
- Fathonah, R., 2018. *Identifikasi Efek Samping Kemoterapi Pada Penderita Kanker Di Yayasan Kanker Sindonesia Mulyorejo*. Skripsi, Universitas Muhammadiyah Surabaya, Surabaya.
- GLOBOCAN, 2020, Cancer Today. Estimated number of new cases in 2020, Indonesia, both sexes, all ages, https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5b%5d=0&ages_group%5b%5d=17&group_cancer=1&i, (diakses pada 29/12/2022).
- GLOBOCAN, 2020, Cancer Today. Estimated number of deaths in 2020, Indonesia, both sexes, all ages, https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=360&key=asr&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5b%5d=0&ages_group%5b%5d=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1#collapse-by_country, (diakses pada 29/12/2022).
- Gradishar, W.J. dkk., 2023. *Breast cancer, version 3.2023, NCCN clinical practice*



guidelines in oncology, JNCCN. National Comprehensive Cancer Network. <https://jncnn.org/view/journals/jnccn/20/6/article-p691.xml> (diakses pada 10 Maret 2023).

Hidayati, M.N., Nisa, F.Z., Putri, A.R., dan Rahayu, P., 2021, “APA ITU KANKER?,” dalam *Bahan Pangan Pencegah Kanker.*, 6–7, Gadjah Mada University Press, D.I. Yogyakarta.

Iancu, G., Serban, D., Badiu, C. D., Tanasescu, C., Tudose, M. S., Tudor, C., Costea, D. O., Zgura, A., Iancu, R., dan Vasile, D., 2022, Tyrosine kinase inhibitors in breast cancer (Review), dalam *Experimental and therapeutic medicine*, 23(2), 114. <https://doi.org/10.3892/etm.2021.11037>.

Ilić, I. R., Stojanović, N. M., Radulović, N. S., Živković, V. V., Randjelović, P. J., Petrović, A. S., Božić, M., dan Ilić, R. S. 2019, The quantitative ER immunohistochemical analysis in breast cancer: Detecting the 3 + 0, 4 + 0, and 5 + 0 allred score cases, dalam *Medicina*, 55(8), 461. <https://doi.org/10.1038/sj.bjc.6600652>.

Jonat, W., 2002, Goserelin (zoladex™) – its role in early breast cancer in pre- and Perimenopausal women, dalam *British Journal of Cancer*, 87(12), 1480–1480. <https://doi.org/10.1038/sj.bjc.6600652>.

Julipriohadi, A., 2015, Analisis Pelayanan Kemoterapi Peserta Badan Penyelenggara Jaminan Sosial di Rawat Singkat Anyelir Rumah Sakit Kanker “Dharmais” dengan Metode Lean Tahun 2015, *Jurnal ARSI*, 2(2) : 84-85

Kaestner, S. A., dan Sewell, G. J. 2007, Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. dalam *Clinical oncology (Royal College of Radiologists (Great Britain))*, 19(1), 23–37. <https://doi.org/10.1016/j.clon.2006.10.010>

Kania, N., 2018, *Payudara & Kelainannya*. PT Grafika Wangi Kalimantan, Banjarmasin

Kementrian Kesehatan Republik Indonesia, 2011, *Modul Penggunaan Obat Rasional*, Bina Pelayanan Kefarmasian, Jakarta.

Kementrian Kesehatan Republik Indonesia, 2017, Panduan Penatalaksanaan Kanker Payudara, <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>. (diakses 29/12/2022).

Liambo, I.S., Frisitiohady, A. dan Malaka, M.H., 2022, Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara. dalam *Pharmauhu: Jurnal Farmasi, Sains, dan Kesehatan*, 8(1), 17–19.

Martin M. 2006, Docetaxel, Doxorubicin and Cyclophosphamide (the TAC Regimen): An Effective Adjuvant Treatment for Operable Breast Cancer. dalam *Women's Health*. 2(4), 527-537.



Mohanty, S.S., Sahoo, C.R. dan Padhy, R.N. 2022, Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update, dalam *Genes & Diseases*, 9(3), 648–658. <https://>

Mukhtar, E., Adhami, V. M., dan Mukhtar, H. 2014. Targeting microtubules by natural agents for cancer therapy. dalam *Molecular cancer therapeutics*, 13(2), 275–284. <https://doi.org/10.1158/1535-7163.MCT-13-0791>.

National Cancer Institute, 2023, Breast cancer treatment—for health professionals(PDQ®), <https://www.cancer.gov/types/breast/hp/breast-treatment-pdq>. (diakses pada 11/03/2023)

Notoatmodjo, S., 2010, *Metodelogi Penelitian Kesehatan*, Rineka Cipta, Jakarta.

Nuraini, N., Megawati, S. dan Wahyuningtyas, D., 2022, Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara Di Rumah Sakit Umum Kabupaten Tangerang. dalam *Jurnal Farmagazine*, IX(2), 34–35.

Patel, H.K. dan Bihani, T., 2018, Selective estrogen receptor modulators (serms) and selective estrogen receptor degraders (serds) in cancer treatment, dalam *Pharmacology & Therapeutics*, 186, 1–24. <https://doi.org/10.1016/j.pharmthera.2017.12.012>.

Purnamaningtyas, S., 2019, Hubungan Tingkat Pengetahuan Tentang Kanker Payudara Terhadap Perilaku Praktik Pemeriksaan Payudara Sendiri (SADARI) Pada Pegawai Radioterapi RSUPN Dr. Cipto Mangunkusumo. Skripsi, Program Ilmu Keperawatan Universitas Binawan, Jakarta

Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., dan Pacilio, G. 2000, A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. dalam *Tumori*, 86(3), 207–210. <https://doi.org/10.1177/030089160008600306>

Singh, R. dan Sain, N. K., 2023, Etiology Of Breast Cancer, dalam *Journal of Pharmaceutical Negative Results*, 14(03), 1428–1431. <https://doi.org/https://doi.org/10.47750/pnr.2023.14.03.192>.

Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., dan Zhu, H. P., 2017, Risk Factors and Preventions of Breast Cancer, dalam *International Journal of Biological Sciences*. 13(11):1387-1397.

Suyatno, dan Pasaribu, E, 2014, Kanker Payudara, dalam *Bedah onkologi Diagnosis dan Terapi*, Edisi 2, Sagung Seto, Jakarta

Tayeb, M., 2020, Pengaruh Permukaan Tubuh Manusia Terhadap Sensasi Termal Dalam Ruang Kelas. Disertasi, Program Studi S3 Ilmu Arsitektur Universitas Hasanuddin, Makassar



Tyagi, N.K. dan Dhesy-Thind, S., 2018, Clinical practice guidelines in breast cancer, dalam *Current Oncology*, 25(11), 151–160.
<https://doi.org/10.3747/co.25.3729>.

Vasey, P. A., Roché, H., Bisset, D., Terret, C., Vernillet, L., Riva, A., Ramazeilles, C., Azli, N., Kaye, S. B., dan Twelves, C. J. 2002, Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. dalam *British journal of cancer*, 87(10), 1072–1078.
<https://doi.org/10.1038/sj.bjc.6600626>

Verbraecken, J., Van de Heyning, P., De Backer, W., & Van Gaal, L., 2006, ‘Body surface area in normal-weight, overweight, and obese adults. A comparison study’, dalam *Metabolism*, 55(4), 515–524.
<https://doi:10.1016/j.metabol.2005.11.004>.

Vu, T., dan Claret, F. X., 2012, Trastuzumab: updated mechanisms of action and resistance in breast cancer. dalam *Frontiers in oncology*, 2, 62.
<https://doi.org/10.3389/fonc.2012.00062>.